Does the media favor HRMY or PTGX?

In the previous week, Protagonist Therapeutics had 4 more articles in the media than Harmony Biosciences. MarketBeat recorded 7 mentions for Protagonist Therapeutics and 3 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.18 beat Protagonist Therapeutics' score of 0.67 indicating that Harmony Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HRMY or PCVX?

In the previous week, Vaxcyte had 2 more articles in the media than Harmony Biosciences. MarketBeat recorded 5 mentions for Vaxcyte and 3 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.18 beat Vaxcyte's score of 0.65 indicating that Harmony Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, HRMY or QGEN?

Qiagen has higher revenue and earnings than Harmony Biosciences. Harmony Biosciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Harmony Biosciences $868.45M 2.32 $158.69M $2.48 14.04 Qiagen $2.09B 4.10 $424.88M $1.91 21.80

Does the media refer more to HRMY or QGEN?

In the previous week, Qiagen had 12 more articles in the media than Harmony Biosciences. MarketBeat recorded 15 mentions for Qiagen and 3 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.18 beat Qiagen's score of 1.04 indicating that Harmony Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 9 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HRMY or APGE?

In the previous week, Apogee Therapeutics had 7 more articles in the media than Harmony Biosciences. MarketBeat recorded 10 mentions for Apogee Therapeutics and 3 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.18 beat Apogee Therapeutics' score of 0.65 indicating that Harmony Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TGTX or HRMY?

In the previous week, TG Therapeutics had 18 more articles in the media than Harmony Biosciences. MarketBeat recorded 21 mentions for TG Therapeutics and 3 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.18 beat TG Therapeutics' score of 0.72 indicating that Harmony Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harmony Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Harmony Biosciences (HRMY) Competitors

$34.81 -0.73 (-2.05%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$34.84 +0.03 (+0.10%)

As of 08:43 AM Eastern

Compare

HRMY vs. PTGX, PCVX, QGEN, APGE, and TGTX

Should you buy Harmony Biosciences stock or one of its competitors? MarketBeat compares Harmony Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Harmony Biosciences include Protagonist Therapeutics (PTGX), Vaxcyte (PCVX), Qiagen (QGEN), Apogee Therapeutics (APGE), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry.

How does Harmony Biosciences compare to Protagonist Therapeutics?

Harmony Biosciences (NASDAQ:HRMY) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Harmony Biosciences has a net margin of 16.20% compared to Protagonist Therapeutics' net margin of -154.88%. Harmony Biosciences' return on equity of 17.19% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	16.20%	17.19%	11.99%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Harmony Biosciences has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market.

In the previous week, Protagonist Therapeutics had 4 more articles in the media than Harmony Biosciences. MarketBeat recorded 7 mentions for Protagonist Therapeutics and 3 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.18 beat Protagonist Therapeutics' score of 0.67 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 11.0% of Harmony Biosciences shares are owned by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Harmony Biosciences presently has a consensus price target of $42.50, suggesting a potential upside of 22.09%. Protagonist Therapeutics has a consensus price target of $119.21, suggesting a potential downside of 9.18%. Given Harmony Biosciences' higher probable upside, equities analysts clearly believe Harmony Biosciences is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

Harmony Biosciences has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45M	2.32	$158.69M	$2.48	14.04
Protagonist Therapeutics	$46.02M	183.44	-$130.15M	-$1.81	N/A

Summary

Harmony Biosciences beats Protagonist Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Harmony Biosciences compare to Vaxcyte?

Harmony Biosciences (NASDAQ:HRMY) and Vaxcyte (NASDAQ:PCVX) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Harmony Biosciences has a net margin of 16.20% compared to Vaxcyte's net margin of 0.00%. Harmony Biosciences' return on equity of 17.19% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	16.20%	17.19%	11.99%
Vaxcyte	N/A	-32.51%	-29.51%

In the previous week, Vaxcyte had 2 more articles in the media than Harmony Biosciences. MarketBeat recorded 5 mentions for Vaxcyte and 3 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.18 beat Vaxcyte's score of 0.65 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harmony Biosciences currently has a consensus target price of $42.50, suggesting a potential upside of 22.09%. Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 53.00%. Given Vaxcyte's stronger consensus rating and higher possible upside, analysts plainly believe Vaxcyte is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Harmony Biosciences has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45M	2.32	$158.69M	$2.48	14.04
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 11.0% of Harmony Biosciences shares are owned by insiders. Comparatively, 3.3% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Harmony Biosciences has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market.

Summary

Harmony Biosciences beats Vaxcyte on 10 of the 16 factors compared between the two stocks.

How does Harmony Biosciences compare to Qiagen?

Harmony Biosciences (NASDAQ:HRMY) and Qiagen (NYSE:QGEN) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Qiagen has higher revenue and earnings than Harmony Biosciences. Harmony Biosciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45M	2.32	$158.69M	$2.48	14.04
Qiagen	$2.09B	4.10	$424.88M	$1.91	21.80

Qiagen has a net margin of 19.16% compared to Harmony Biosciences' net margin of 16.20%. Harmony Biosciences' return on equity of 17.19% beat Qiagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	16.20%	17.19%	11.99%
Qiagen	19.16%	14.40%	8.40%

In the previous week, Qiagen had 12 more articles in the media than Harmony Biosciences. MarketBeat recorded 15 mentions for Qiagen and 3 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.18 beat Qiagen's score of 1.04 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	9 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harmony Biosciences presently has a consensus price target of $42.50, indicating a potential upside of 22.09%. Qiagen has a consensus price target of $43.34, indicating a potential upside of 4.11%. Given Harmony Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Harmony Biosciences is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Qiagen	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36

Harmony Biosciences has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Qiagen has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 11.0% of Harmony Biosciences shares are owned by company insiders. Comparatively, 9.0% of Qiagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Harmony Biosciences beats Qiagen on 9 of the 15 factors compared between the two stocks.

How does Harmony Biosciences compare to Apogee Therapeutics?

Harmony Biosciences (NASDAQ:HRMY) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Harmony Biosciences presently has a consensus price target of $42.50, indicating a potential upside of 22.09%. Apogee Therapeutics has a consensus price target of $121.25, indicating a potential downside of 9.48%. Given Harmony Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Harmony Biosciences is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24

Harmony Biosciences has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45M	2.32	$158.69M	$2.48	14.04
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

86.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 11.0% of Harmony Biosciences shares are held by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Harmony Biosciences has a net margin of 16.20% compared to Apogee Therapeutics' net margin of 0.00%. Harmony Biosciences' return on equity of 17.19% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	16.20%	17.19%	11.99%
Apogee Therapeutics	N/A	-32.64%	-31.25%

In the previous week, Apogee Therapeutics had 7 more articles in the media than Harmony Biosciences. MarketBeat recorded 10 mentions for Apogee Therapeutics and 3 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.18 beat Apogee Therapeutics' score of 0.65 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harmony Biosciences has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Summary

Harmony Biosciences beats Apogee Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Harmony Biosciences compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Harmony Biosciences (NASDAQ:HRMY) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

In the previous week, TG Therapeutics had 18 more articles in the media than Harmony Biosciences. MarketBeat recorded 21 mentions for TG Therapeutics and 3 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.18 beat TG Therapeutics' score of 0.72 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harmony Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has a net margin of 65.95% compared to Harmony Biosciences' net margin of 16.20%. TG Therapeutics' return on equity of 88.73% beat Harmony Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Harmony Biosciences	16.20%	17.19%	11.99%

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by company insiders. Comparatively, 11.0% of Harmony Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

TG Therapeutics has higher earnings, but lower revenue than Harmony Biosciences. Harmony Biosciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	13.63	$447.18M	$2.86	19.19
Harmony Biosciences	$868.45M	2.32	$158.69M	$2.48	14.04

TG Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

TG Therapeutics presently has a consensus target price of $53.33, suggesting a potential downside of 2.84%. Harmony Biosciences has a consensus target price of $42.50, suggesting a potential upside of 22.09%. Given Harmony Biosciences' higher probable upside, analysts plainly believe Harmony Biosciences is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Harmony Biosciences	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

TG Therapeutics beats Harmony Biosciences on 10 of the 15 factors compared between the two stocks.

Get Harmony Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HRMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HRMY vs. The Competition

Export

Metric	Harmony Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.06B	$3.68B	$6.86B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	14.04	20.98	26.94	24.38
Price / Sales	2.32	311.10	521.23	91.92
Price / Cash	11.18	143.66	48.59	59.36
Price / Book	2.30	8.54	10.89	6.33
Net Income	$158.69M	$23.83M	$3.59B	$331.02M
7 Day Performance	-8.59%	-2.77%	-1.53%	-0.33%
1 Month Performance	1.84%	5.85%	2.72%	-1.29%
1 Year Performance	-0.09%	52.15%	28.47%	21.30%

Harmony Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HRMY Harmony Biosciences	4.7884 of 5 stars	$34.81 -2.1%	$42.50 +22.1%	+0.3%	$2.06B	$868.45M	14.04	200	News Coverage Positive News Analyst Upgrade
PTGX Protagonist Therapeutics	1.5317 of 5 stars	$131.50 -0.1%	$115.21 -12.4%	+137.7%	$8.46B	$46.02M	N/A	120	Analyst Forecast
PCVX Vaxcyte	2.5171 of 5 stars	$56.96 -2.4%	$86.00 +51.0%	+54.5%	$8.43B	N/A	N/A	160
QGEN Qiagen	4.1327 of 5 stars	$39.15 -2.4%	$43.15 +10.2%	-18.0%	$8.26B	$2.09B	20.45	5,654	Positive News Analyst Forecast Gap Down
APGE Apogee Therapeutics	1.8338 of 5 stars	$133.50 +0.4%	$121.25 -9.2%	+244.5%	$8.23B	N/A	N/A	91	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HRMY) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harmony Biosciences (HRMY) Competitors

HRMY vs. PTGX, PCVX, QGEN, APGE, and TGTX

How does Harmony Biosciences compare to Protagonist Therapeutics?

Summary

How does Harmony Biosciences compare to Vaxcyte?

Summary

How does Harmony Biosciences compare to Qiagen?

Summary

How does Harmony Biosciences compare to Apogee Therapeutics?

Summary

How does Harmony Biosciences compare to TG Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRMY vs. The Competition

Harmony Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harmony Biosciences (HRMY) Competitors

HRMY vs. PTGX, PCVX, QGEN, APGE, and TGTX

How does Harmony Biosciences compare to Protagonist Therapeutics?

Is HRMY or PTGX more profitable?

Which has more volatility and risk, HRMY or PTGX?

Does the media favor HRMY or PTGX?

Do institutionals and insiders hold more shares of HRMY or PTGX?

Do analysts rate HRMY or PTGX?

Which has stronger earnings & valuation, HRMY or PTGX?

Summary

How does Harmony Biosciences compare to Vaxcyte?

Is HRMY or PCVX more profitable?

Does the media refer more to HRMY or PCVX?

Do analysts rate HRMY or PCVX?

Which has better valuation & earnings, HRMY or PCVX?

Do institutionals & insiders hold more shares of HRMY or PCVX?

Which has more risk & volatility, HRMY or PCVX?

Summary

How does Harmony Biosciences compare to Qiagen?

Which has preferable earnings & valuation, HRMY or QGEN?

Is HRMY or QGEN more profitable?

Does the media refer more to HRMY or QGEN?

Do analysts prefer HRMY or QGEN?

Which has more volatility & risk, HRMY or QGEN?

Do institutionals & insiders believe in HRMY or QGEN?

Summary

How does Harmony Biosciences compare to Apogee Therapeutics?

Do analysts prefer HRMY or APGE?

Which has better earnings and valuation, HRMY or APGE?

Do insiders and institutionals believe in HRMY or APGE?

Is HRMY or APGE more profitable?

Does the media refer more to HRMY or APGE?

Which has more risk & volatility, HRMY or APGE?

Summary

How does Harmony Biosciences compare to TG Therapeutics?

Does the media favor TGTX or HRMY?

Is TGTX or HRMY more profitable?

Do institutionals & insiders have more ownership in TGTX or HRMY?

Which has stronger earnings & valuation, TGTX or HRMY?

Which has more volatility & risk, TGTX or HRMY?

Do analysts prefer TGTX or HRMY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRMY vs. The Competition

Harmony Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools